News

Value investing is a rather popular investing strategy. Seeing as almost everyone enjoys buying great products at discounted prices, it isn't surprising that we would also like to get good deals on

Abbott Laboratories (NYSE: ABT) posted its latest earnings numbers last month, and there's reason to be optimistic about the business. Although a drop in COVID testing means sales are down overall

In the realm of investing, market capitalization is a good but not perfect way to gauge the success of a business. Sure, sometimes companies are overvalued. But a company's market value can at least

Biogen (NASDAQ: BIIB) is an intriguing stock right now. Its business has struggled to generate growth in recent years, but some recent catalysts could turn things around. For starters, the company's

Investing for income may never be the most exciting investment strategy in the world. But as long as a company doesn't cut or suspend its dividend, it can be a profitable approach -- and some

Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) has made for a solid investment over the past decade, more than quadrupling in value during that period. The stock generated fantastic returns

The cost of living is getting more and more expensive. This is because inflation steadily diminishes the value of the U.S. dollar over time, and the purchasing power of said dollar as a result.

One

Merck (NYSE: MRK) has performed poorly in the stock market this year, with the drugmaker's shares down by 5%. But zooming out helps put a different spin on this story as the pharmaceutical giant has

If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming. If you look specifically at biotech

If you're looking for stocks that can deliver better-than-average returns in the long run, you might want to consider these two biotechs: Exact Sciences (NASDAQ: EXAS) and Vertex Pharmaceuticals

GDP grew at a rate of 2.4% in the second quarter as the economy did better than expected. And many businesses are also seeing strong demand for their products and services. That, in turn, leads to

Alzheimer's patients could soon have more treatment options available. Biogen's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli

Pfizer (NYSE: PFE) provides investors with an attractive dividend that currently yields 4.7%. To collect $1,000 in annual dividends at that rate, you would need to invest approximately $21,300

One of the great things about investing in stocks is that there is no need to have millions in the bank to get started. A relatively modest sum such as $1,000 can go a long way if invested shrewdly

Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news. After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it

As one of the hottest and most-watched companies in the biopharmaceutical sector, Vertex Pharmaceuticals (NASDAQ: VRTX) has a unique mix of stability and growth potential that's attractive to a

Buying industry-leading companies in industries with growth potential tends to produce delightful results for dividend investors. This is because such businesses can generate revenue and earnings

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q2 2023 Earnings CallAug 08, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE), a company that focuses on developing therapies for brain disorders. The stock plummeted by more than 53% after the company revealed that

How do you know when a former favorite dividend stock is no longer one you should buy, or hold? Some would say it's time to look away as soon as the profits the company uses to make dividend

Income-seeking investors tend to be drawn to high dividend yields. The higher the yield, the better a dividend becomes at generating income that can fund an investor's spending as well as beat

The right companies can help investors improve their personal balance sheets. That is because businesses that reliably grow sales and earnings become more valuable to financial markets with each

A monster revenue miss was the big reason for the widespread investor sell-off in BioNTech (NASDAQ: BNTX) stock on Monday. As of late-session trading that day, the once-hot biotech's share price had

Shares of Sage Therapeutics (NASDAQ: SAGE) were crashing 51.2% lower as of 11:27 a.m. ET on Monday. The huge sell-off came after the company and its partner, Biogen, announced following the market

Last year was no small challenge for many investors, but the tides appear to have shifted for the better so far in 2023. Some companies have even performed well throughout all these ups and downs.